Nuvalent (NUVL)
(Delayed Data from NSDQ)
$72.87 USD
+0.82 (1.14%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $72.80 -0.07 (-0.10%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NUVL 72.87 +0.82(1.14%)
Will NUVL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NUVL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVL
Why Earnings Season Could Be Great for Nuvalent (NUVL)
Nuvalent (NUVL) Soars 36% on Upbeat Initial NSCLC Study Data
NUVL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
Are Medical Stocks Lagging DICE Therapeutics (DICE) This Year?
Other News for NUVL
Nuvalent: Making Precise Progress In Its Oncology Pipeline
3 Short-Squeeze Stocks Poised for a Jaw-Dropping Rally
Nuvalent: NVL-655 Could Bring Blockbuster Potential
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Nuvalent’s NVL-655 Poised to Redefine First-Line ALK+ NSCLC Therapy